From vascular advancements to visions of organ transplants, our regenerative innovations are harnessing the body’s own ability to heal.
Humacyte’s platform technology has the potential to change the lives of countless people around the world by overcoming the current limitations in existing standards of care. We are leveraging our scalable technology platform to develop bioengineered human tissues for use in the treatment of diseases and conditions across a wide range of clinical needs. We are initially using our technology to bioengineer and manufacture human acellular vessels, or HAVs, in varying sizes to address the significant unmet needs across multiple potential indications in vascular repair, reconstruction and replacement. HAVs are currently being investigated across multiple clinical trials in vascular trauma, AV access for hemodialysis, and peripheral arterial disease. Our pipeline vision is to evolve the utility of the HAV technology and develop future opportunities for coronary artery bypass grafting, pediatric heart surgery, the delivery of cellular therapies- including transplant of islet cells to treat Type 1 diabetes patients, and one day engineered solutions for complex tissue systems and organ transplants.
Trachea 1 of 9
Vascular Trauma 3 of 9
Esophagus2 of 9
Dialysis AV Access4 of 9
Peripheral Arterial Disease (PAD)5 of 9
Coronary Artery Bypass Grafting (CABG)6 of 9
Lung7 of 9
Pancreas8 of 9
Urinary Conduit9 of 9